Moderna, Inc.
mRNA-1273.214 Exhibited a Greater Than 5-Fold Boost in Neutralizing Antibodies Against BA.4 and BA.5 Subvariants in Phase 2/3 Study
Data Being Submitted to Regulators and for Peer Reviewed Publication
CAMBRIDGE, MA / ACCESSWIRE / June 22, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its bivalent (Omicron) COVID booster candidate, mRNA-1273.214. One month after administration in previously vaccinated and boosted participants, a 50 µg booster dose of mRNA-1273.214 elicited potent neutralizing antibody responses against the Omicron subvariants BA.4 and BA.5 in all participants regardless of prior infection. Based on this and prior data, the Company is working to complete regulatory submissions in the coming weeks requesting to update the composition of the booster vaccine to mRNA-1273.214.
In today's data, mRNA-1273.214 boosted neutralizing titers against BA.4/BA.5 by 5.4-fold (95% CI: 5.0, 5.9) above baseline in all participants regardless of prior infection, and by 6.3-fold (95% CI: 5.7, 6.9) in the subset of seronegative participants. Neutralizing titers against BA.4/BA.5 were approximately 3-fold lower than previously reported neutralizing titers against BA.1. One month after an mRNA-1273.214 booster, neutralizing geometric mean titers (GMT) against BA.4/BA.5 were 941 (95% CI: 826, 1071) in all participants, and 727 (95% CI: 633, 836) in seronegative participants. For context, prior studies of a third dose of the prototype booster induced neutralizing GMT against BA.1 of 629 (95% CI: 526, 751) and against Delta of 828 (95% CI: 738, 928)[1]. A third dose of the prototype booster was shown to be effective against Delta and BA.1 infection and hospitalization in observational studies [2],[3].
"In the face of SARS-CoV-2's continued evolution, we are very encouraged that mRNA-1273.214, our lead booster candidate for the fall, has shown high neutralizing titers against the BA.4 and BA.5 subvariants, which represent an emergent threat to global public health," said Stéphane Bancel, Chief Executive Officer of Moderna. "We will submit these data to regulators urgently and are preparing to supply our next generation bivalent booster starting in August, ahead of a potential rise in SARS-CoV-2 infections due to Omicron subvariants in the early fall."
Today's data add to results shared earlier this month from the Company's ongoing Phase 2/3 study in approximately 800 participants. Previous results showed a 50 µg booster dose of mRNA-1273.214 met all pre-specified primary endpoints, including superiority in neutralizing antibody GMT against Omicron (BA.1) when compared to a 50 µg booster dose of the prototype booster (mRNA-1273). The bivalent booster was generally well tolerated, with a reactogenicity and safety profile that was consistent with the prototype booster. Moderna believes these data collectively support updating the composition of the Company's booster to bivalent (Omicron) mRNA-1273.214 for the fall.
The Company has already shared these data with regulators and is submitting a manuscript for peer reviewed publication.
About Moderna
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company's development of a bivalent booster vaccine targeted at the Omicron variant of the SARS-CoV-2 virus (mRNA-1273.214); the ability of mRNA-1273.214 to trigger an antibody response against the Omicron subvariants BA.4 and BA.5; the Company's submission of data to regulators in support of authorization of mRNA-1273.214 as a fall booster; and the safety and tolerability profile of mRNA-1273.214. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading "Risk Factors" in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof.
Moderna Contacts
Media:
Chris Ridley
617-800-3651
Vice President, Corporate Communications & Head of Media
Chris.Ridley@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View source version on accesswire.com:
https://www.accesswire.com/706099/Moderna-Announces-Bivalent-Booster-mRNA-1273214-Demonstrates-Potent-Neutralizing-Antibody-Response-Against-Omicron-Subvariants-BA4-And-BA5
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AI and Cybersecurity Leader, SecureAuth, Appoints Geoffrey Mattson to Help Enterprises Secure Complex Human, Machine, and AI-agent Identities10.12.2025 17:30:00 CET | Press release
IRVINE, CALIFORNIA / ACCESS Newswire / December 10, 2025 / SecureAuth, a leader in AI-driven identity security, today announced the appointment of Geoffrey Mattson as Chief Executive Officer. Mattson's appointment marks the beginning of the company's next phase of growth as enterprises confront a rapid rise in AI agents with real authority, a shift that is increasing the complexity of business relationships and driving urgent demand for modern identity security. The Board of Directors thanks outgoing CEO Joseph Dhanapal, who will remain as a strategic advisor. During his tenure, SecureAuth invested heavily in creating a next generation security platform, featuring our market leading, AI-driven risk engine. With this platform in place, SecureAuth is positioned to capture accelerating demand for identity and access management as agentic AI transforms identity from a static access check into a dynamic control plane for managing complex human, machine, and AI-driven relationships. Mattson
Nasdaq Verafin Joins Global Anti-Scam Alliance10.12.2025 15:00:00 CET | Press release
THE HAGUE, NL / ACCESS Newswire / December 10, 2025 / The Global Anti-Scam Alliance (GASA) is pleased to announce that Nasdaq Verafin has joined GASA as a Foundation Member, strengthening the global effort to combat scams, financial crime, and digital fraud. As fraud tactics continue to evolve across borders and digital channels, cross-sector collaboration has become essential to protecting consumers and building safer financial ecosystems. Nasdaq Verafin's participation marks a meaningful step forward in the shared mission to advance trust, transparency, and resilience across the globe. In addition to joining the global effort, Nasdaq Verafin will join both the Brazil and Mexico chapters of GASA to partner with stakeholders across the financial ecosystem in Latin America, bolstering regional initiatives to combat financial crime. "Criminals are innovating at an unprecedented rate, taking advantage of information siloes and the shortcomings of legacy technology to avoid detection. We a
TIS Helps Treasury Teams Navigate the Ongoing ISO 20022 Transition After the 2025 Banking Deadline10.12.2025 14:00:00 CET | Press release
BERLIN, DE / ACCESS Newswire / December 10, 2025 / Treasury Intelligence Solutions (TIS), a leading cloud-based platform for payments and cash management, is future-proofing organizations with specialized translation services in the wake of the recent November 2025 ISO 20022 deadline. A major turning point for the financial industry, SWIFT now requires banks to move their cross-border payment messages to ISO 20022. As a result, treasury teams are already seeing differences in how their banks send and receive payment information. Adapting to these changes will require a strategic approach to modernizing systems and processes. ISO 20022 replaces a patchwork of older standards with a single approach to structuring payment data. The new universal standard is designed to reduce confusion across markets, improve data quality, and support the level of transparency that regulators around the globe now expect. Moving to ISO 20022 payments takes time and strategic vision, especially when legacy
Majority of Australian Parents (65%) and U.S. Parents 58% Support Social Media Ban for Under 16s, but Kids Say It Risks Cutting Them Off from Key Connections9.12.2025 15:00:00 CET | Press release
New survey of 4,000 parents and children in the U.S. and Australia reveals sharp generational divides in support, fears, mental health expectations, and belief in government enforcement. WASHINGTON, DC / ACCESS Newswire / December 9, 2025 / The Family Online Safety Institute (FOSI) released new research today examining how parents and children in the United States and Australia view social media bans for anyone under 16. The findings reveal strong parental support for such bans, in contrast with widespread concern from children who fear losing friendships and support systems that exist primarily online. The research arrives as Australia implements a national under 16 social media ban, placing global attention on how the policy will affect youth and their families. FOSI's study surveyed 4,000 parents and children ages 10 to 17 to understand how both groups feel about restrictions, enforcement, and the broader impact of social media on daily life. Support for the Ban: Parents vs Children
Techmer PM Joins Formerra's Portfolio in North America9.12.2025 15:00:00 CET | Press release
Formerra will distribute Techmer PM color masterbatches, high-performance additives, and pre-colored compounds across the U.S., Canada, and Mexico. ROMEOVILLE, ILLINOIS / ACCESS Newswire / December 9, 2025 / Formerra, a leader in performance materials distribution, today announced the addition of Techmer PM color masterbatches, high-performance additives, and pre-colored compounds to its expansive portfolio of materials. With this partnership, Formerra advances its application-specific lineup, aligning its material portfolio to customers' evolving needs across North America. A U.S.-based plastics compounder, Techmer PM specializes in value-added color and additive masterbatches and engineered compounds for high-performance plastics and fibers. These products are used in various industries such as medical, automotive, packaging, and consumer goods applications. Techmer PM has consistently invested in its optical and color capabilities, including the recent acquisition of OptiColor Inc.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom